# PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

> **NCT06479187** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Metastatic Prostate Cancer
- Hormone Sensitive Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

## Interventions

- **DRUG:** 18F-rhPSMA-7.3
- **DEVICE:** PET/CT

## Key facts

- **NCT ID:** NCT06479187
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-30
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-06-20
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-11-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06479187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06479187, "PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06479187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*